1、以3票同意、0票反对和0票弃权的表决结果，审核通过了《公司2025年半 年度报告及其摘要》。 证券代码：002020 证券简称：京新药业 公告编号：2025040 浙江京新药业股份有限公司 第八届监事会第十三次会议决议公告 浙江京新药业股份有限公司（以下简称"公司"）第八届监事会第十三次会 议通知于 2025 年 8 月 15 日以电子邮件形式发出，会议于 2025 年 8 月 26 日在公 司行政楼一楼会议室召开。会议应到监事三名，实到三名，符合《公司法》和《公 司章程》的有关规定。会议由监事会主席胡天庆主持，会议审核并一致通过了如 下决议： 监事会认为：经审核，监事会认为董事会编制和审核浙江京新药业股份有限 公司2025年半年度报告的程序符合法律、行政法规和中国证监会的规定，报告内 容真实、准确、完整地反映了上市公司的实际情况，不存在任何虚假记载、误导 性陈述或者重大遗漏。 2、以3票同意、0票反对和0票弃权的表决结果，审核通过了《公司2025年半 年度募集资金存放与使用情况的专项报告》。 3、以 3 票同意，0 票反对和 0 票弃权的表决结果，审核通过了《关于使用 部分闲置募集资金暂时补充流动资金的 ...

证券代码：002020 证券简称：京新药业 公告编号：2025039 浙江京新药业股份有限公司 第八届董事会第十六次会议决议公告 浙江京新药业股份有限公司(以下简称"公司")第八届董事会第十六次 会议通知于 2025 年 8 月 15 日以电子邮件形式发出，会议于 2025 年 8 月 26 日以电话及传真方式召开。会议应参加表决的董事 9 名，实际参加表决的董 事 9 名。会议召开符合《公司法》和《公司章程》的规定。会议经表决形成 决议如下： 1、以 9 票同意、0 票反对和 0 票弃权的表决结果，审议通过了《公司 2025 年半年度报告及摘要》。半年报全文详见指定信息披露网站巨潮资讯网 http://www.cninfo.com.cn；半年报摘要详见公司在《证券时报》、《中国证券 报》和巨潮资讯网 http://www.cninfo.com.cn 上刊登的 2025041 号公告。 2、以 9 票同意、0 票反对和 0 票弃权的表决结果，审议通过了《公司 2025 年半年度募集资金存放与使用情况的专项报告》，详见公司在《证券时报》、《中 国证券报》和巨潮资讯网 http://www.cninfo.com. ...

Summary of Key Points Core Viewpoint - The company, Zhejiang Jingxin Pharmaceutical Co., Ltd., is utilizing part of its idle raised funds to temporarily supplement its working capital, which is expected to enhance fund efficiency and reduce financial costs [1][3]. Group 1: Fundraising Overview - In 2021, the company completed a non-public offering of 67,567,567 shares at a price of RMB 7.40 per share, raising a total of RMB 495,040,026.39 [1]. - The raised funds are designated for the construction of a digital workshop for solid preparations with a total investment of RMB 647,918,100 [2]. Group 2: Temporary Use of Idle Funds - The company plans to use up to RMB 290 million of idle funds to supplement working capital, with a usage period not exceeding 12 months, from the board's approval date until August 13, 2025 [2][3]. - This temporary use of funds is expected to save approximately RMB 2.6 million in financial costs during the period [3]. Group 3: Compliance and Approval - The decision to use idle funds has been approved by the company's board and supervisory board, adhering to necessary legal and regulatory procedures [5][6]. - The company commits to returning the funds to the special account by the end of the usage period and assures that this action will not alter the intended use of the raised funds or affect project progress [3][5].

浙江京新药业股份有限公司 2025 年半年度报告全文 浙江京新药业股份有限公司 2025 年半年度报告 2025 年 08 月 1 浙江京新药业股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人吕钢、主管会计工作负责人陈美丽及会计机构负责人(会计主 管人员)周叶珍声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 公司面临的风险详见本报告"第三节管理层讨论与分析"之"十、公司 面临的风险和应对措施"。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 浙江京新药业股份有限公司 2025 年半年度报告全文 备查文件目录 1、载有公司法定代表人、主管会计工作负责人、会计机构负责人签名并盖章的财务报 表。 2、报告期内在中国证监会指定网站上公开披露过的所有公司文件的正本及公告的原稿。 3、经公司董事长签名的 2025 年半年度报告原件。 4、以上备查文件的备置地点：董事会 ...

Group 1 - The company reported a revenue of 2.017 billion yuan for the first half of 2025, representing a year-on-year decline of 6.20% [1] - The net profit for the same period was 388 million yuan, showing a year-on-year decrease of 3.54% [1] - The company announced plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves [1]

Core Viewpoint - The company has submitted a listing application for its hydrochloride cariprazine capsules, which currently do not meet the criteria for priority review, and is preparing to cooperate with regulatory approval processes to expedite market entry for new treatment options for patients [1] Group 1 - The listing application for hydrochloride cariprazine capsules has been submitted [1] - The project does not currently meet the priority review criteria [1] - The company is committed to preparing and cooperating with regulatory approval processes [1]

证券之星消息，8月21日化学制药板块较上一交易日上涨0.09%，*ST苏吴领涨。当日上证指数报收于 3771.1，上涨0.13%。深证成指报收于11919.76，下跌0.06%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600200 | *ST苏吴 | 0.96 | 5.49% | 43.67万 | | 4141.60万 | | 300705 | 九典制药 | 19.87 | 4.97% | 52.35万 | | 10.35 Z | | 300573 | 兴齐眼药 | 67.48 | 4.69% | 22.77万 | | 15.19 Z | | 688506 | 百利天恒 | 324.96 | 4.21% | 1.62万 | | 5.23亿 | | 002940 | 昂利康 | 51.36 | 3.86% | 15.16万 | | 7.69亿 | | 002020 | 京新药业 | 19.52 | 2.90% | 32.05万 | | 6.16 ...

Core Points - Zhejiang Jingxin Pharmaceutical Co., Ltd. has approved the temporary use of idle raised funds to supplement working capital, not exceeding 290 million yuan [1] - The funds include 90 million yuan from the 2016 non-public offering and 200 million yuan from the 2020 non-public offering, with a usage period of up to 12 months [1] - As of March 21, 2025, the company has fully returned the 90 million yuan from the 2016 offering to the designated account, which was subsequently closed on April 7, 2025 [2] - By August 13, 2025, the company has also returned the 200 million yuan from the 2020 offering to the designated account, totaling 290 million yuan returned [2] Summary by Sections - **Company Announcement**: The company held its eighth board meeting on August 14, 2024, to approve the temporary use of idle funds [1] - **Fund Return Status**: The company has successfully returned all raised funds to the designated account within the stipulated time frame [2] - **Closure of Accounts**: The designated account for the 2016 offering was officially closed after all funds were utilized [2]

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：公司人工大血管项目进展如何，有没有可能BD？ 京新药业（002020.SZ）8月15日在投资者互动平台表示，公司人工大血管项目已经进入到临床试验阶 段。后续情况请关注相关公告。 ...

Core Viewpoint - The company is actively promoting its Alzheimer's treatment drugs, aiming to capture a larger market share in the healthcare sector [2] Company Summary - The company, Jingxin Pharmaceutical (002020.SZ), has two drugs for Alzheimer's treatment: Methylphenidate Hydrochloride Sustained-Release Capsules and Carbamazepine Tartrate Capsules [2] - The company is committed to increasing sales and market presence for these drugs [2] Industry Summary - There is a competitive landscape in the Alzheimer's treatment market, with the company focusing on expanding its reach in both hospital channels and grassroots markets [2]